Pfizer Inc. (PFE) — Fair Value Analysis

Base-case fair value (P50): $22.64 · Current price: $25.33 · Verdict: Fairly Valued

The Verdict on PFE

Based on robust Monte Carlo simulations, Pfizer (PFE) is currently assessed as Fairly Valued. While the current price of $26.48 sits above the median fair value (P50) of $21.44, representing a -19.0% difference, the overall distribution of potential outcomes suggests PFE's valuation is balanced at present. This nuanced verdict for the Healthcare sector company incorporates a wide range of forward-looking scenarios, weighing both potential downsides and upsides to arrive at a comprehensive assessment.

How PFE stacks up against Healthcare

PFE's operational and financial health against its sector peers is classified as "weak." This quality tier indicates that, relative to the broader Healthcare sector, Pfizer exhibits particular characteristics in its fundamental performance. When considered alongside the Monte Carlo derived median fair value (P50) of $21.44 versus the current price of $26.48, this "weak" quality tier reinforces the importance of a comprehensive valuation approach. Investors should note this relative positioning when evaluating the current market price.

What this means for investors

Investors evaluating PFE at its current price of $26.48 should understand that the Fairly Valued assessment incorporates the full spectrum of simulated future scenarios. While the median fair value of $21.44 suggests potential downside from the current level, the Monte Carlo framework integrates the company's "weak" quality tier and various market dynamics to provide a balanced view. For a complete understanding of the bear and bull case scenarios, including the full distribution of fair values and the probability of upside, sign up for FairCurve to track PFE's fair value as new fundamentals are released.